Loading…
Alkosign (BSE 543453)₹63.82+10.03%Stationary
In the Mar 2026 quarter (consolidated), Alkosign reported sales of ₹11.06 Cr, down 25.9% from Mar 2025, and net profit of −₹5.16 Cr, down 1,197.9% year on year. For the year to Mar 2026, sales were ₹26.65 Cr and net profit −₹4.77 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 21.21 | 14.40 | 27.84 | 14.92 | 26.31 | 11.06 |
| Expenses | 12.70 | 18.60 | 23.15 | 12.35 | 24.46 | 10.20 |
| Operating Profit | 8.61 | −4.08 | 4.83 | 2.64 | 1.94 | 0.93 |
| OPM % | 40.4% | −28.4% | 17.3% | 17.7% | 7.4% | 8.3% |
| Other Income | 0.03 | 0.23 | 0.14 | −0.18 | 0.15 | −4.46 |
| Interest | 0.46 | 1.23 | 0.52 | 0.24 | 0.61 | 0.30 |
| Depreciation | 1.19 | 1.24 | 1.16 | 0.91 | 1.10 | 1.00 |
| Profit before tax | 7.00 | −6.33 | 3.32 | 1.32 | 0.41 | −4.86 |
| Tax % | 17.1% | −20.6% | 0.0% | 65.0% | 0.0% | 6.2% |
| Exceptional items | 0.00 | 0.00 | 0.00 | −0.33 | 0.00 | −4.49 |
| Net Profit | 5.82 | −5.04 | 3.32 | 0.47 | 0.40 | −5.16 |
| EPS (Rs) | 5.36 | −4.66 | 3.05 | 0.44 | 0.35 | −4.76 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 35.61 | 51.43 | 26.65 |
| Expenses | 31.31 | 43.91 | 23.06 |
| Operating Profit | 4.50 | 7.80 | 3.73 |
| OPM % | 12.6% | 15.1% | 13.9% |
| Other Income | 0.27 | 0.31 | −5.81 |
| Interest | 1.68 | 1.10 | 0.50 |
| Depreciation | 2.44 | 2.41 | 1.86 |
| Profit before tax | 0.68 | 4.63 | −4.47 |
| Tax % | −16.3% | 18.5% | 6.8% |
| Exceptional items | 0.00 | 0.00 | −5.98 |
| Net Profit | 0.79 | 3.78 | −4.77 |
| EPS (Rs) | 0.73 | 3.50 | −4.40 |
| Dividend payout % | 9.2% | 0.0% | 0.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 7.18 | 7.20 | 10.76 |
| Reserves | 21.93 | 25.72 | 17.37 |
| Borrowings | 13.81 | 12.54 | 13.17 |
| Other Liabilities | 6.73 | 5.48 | 3.53 |
| Total Liabilities | 49.65 | 50.94 | 44.83 |
| Fixed Assets | 16.86 | 16.26 | 14.04 |
| CWIP | 0.62 | 0.55 | 0.30 |
| Investments | 0.09 | 0.00 | 0.00 |
| Other Assets | 32.08 | 34.13 | 30.49 |
| Inventories | 16.26 | 17.12 | 9.63 |
| Trade receivables | 5.64 | 11.98 | 12.86 |
| Cash & equivalents | 6.55 | 3.28 | 5.41 |
| Total Assets | 49.65 | 50.94 | 44.83 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | −0.80 | 0.84 | 1.62 |
| Cash from investing activity | −1.58 | −1.75 | 0.35 |
| Cash from financing activity | 8.07 | −2.39 | 0.17 |
| Net cash flow | 5.69 | −3.28 | 2.14 |
| Capex | 1.69 | 1.79 | 1.91 |
| Free cash flow | −2.39 | −0.81 | 2.09 |
| CFO / OP % | −20.0% | 22.0% | 51.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 59 | 86 | 177 |
| Inventory days | 278 | 203 | 225 |
| Days payable | 98 | 48 | 51 |
| Cash conversion cycle | 238 | 240 | 350 |
| Working capital days | 109 | 120 | 151 |
| ROCE % | — | 12.8% | 4.7% |
For the Mar 2026 quarter, Alkosign reported sales of ₹11.06 Cr, down 25.9% year on year and net profit of −₹5.16 Cr, down 1,197.9% year on year. The operating margin was 8.3%.
Alkosign's sales for the year to Mar 2026 were ₹26.65 Cr.
Net profit for the year to Mar 2026 was −₹4.77 Cr. Earnings per share over the same trailing period were ₹−4.40.
Alkosign reported borrowings of ₹13.17 Cr at Mar 2026, against cash and equivalents of ₹5.41 Cr.
Cash from operations was ₹1.62 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹2.09 Cr.